Modality
ASO
MOA
MALT1i
Target
CD38
Pathway
Tau
ObesityCF
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Dec 2030
Phase 1Current
NCT07076935
666 pts·Obesity
2020-12→2030-12·Active
NCT06078282
2,807 pts·CF
2018-05→TBD·Completed
3,473 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-094.7y awayInterim· Obesity
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2030-12-09 · 4.7y away
Obesity
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07076935 | Phase 1 | Obesity | Active | 666 | CfB |
| NCT06078282 | Phase 1 | CF | Completed | 2807 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 |